

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04141 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/00

D-64665 Alsbach (DE). MATZKU, Siegfried [DE/DE];  
Wetzbach 24, D-64673 Zwingenberg (DE). WILBERT,  
Oliver [DE/DE]; Liebfrauenstrasse 54, D-64289 Darm-  
stadt (DE).

(21) International Application Number: PCT/EP00/06211

(22) International Filing Date: 4 July 2000 (04.07.2000)

(74) Common Representative: MERCK PATENT GMBH;  
Frankfurter Str. 250, D-64293 Darmstadt (DE).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): CA, JP, US.

(30) Priority Data:  
99113428.9 12 July 1999 (12.07.1999) EP

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(71) Applicant (*for all designated States except US*): MERCK  
PATENT GMBH [DE/DE]; Frankfurter Str. 250, D-64293  
Darmstadt (DE).

**Published:**

— *Without international search report and to be republished  
upon receipt of that report.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SÜNDERMANN,  
Britta [DE/DE]; Weinbergstrasse 6a, D-64285 Darmstadt  
(DE). HOFMANN, Uwe [DE/DE]; Hähnleinerstr. 42,

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SERIPANCRIN

(57) Abstract: Seripancrin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant tech-  
niques are disclosed. Als disclosed are methods for utilizing Seripancrin polypeptides and polynucleotides in diagnostic assays.

WO 01/04141 A2

## Seripancrin

### Field of the Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „Seripancrin“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

### Background of the Invention

10 The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

20 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

### Summary of the Invention

30 The present invention relates to Seripancrin, in particular Seripancrin polypeptides and Seripancrin polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of

- 2 -

interest in relation to methods of treatment of certain diseases, including, but not limited to, cancer, osteoporosis, aberrant wound healing, angiogenesis, inflammatory disorders, chronic obstructive pulmonary disorder, diabetes, arthritis, stroke and cardiovascular diseases, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with Seripancrin imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate Seripancrin activity or levels.

### Description of the Invention

In a first aspect, the present invention relates to Seripancrin polypeptides. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence selected from SEQ ID NO:1;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence selected from SEQ ID NO:2;
- (c) an isolated polypeptide comprising the polypeptide sequence selected from SEQ ID NO:2;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence from SEQ ID NO:2;
- (e) the polypeptide sequence selected from SEQ ID NO:2; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence selected from SEQ ID NO:2;
- (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the serine protease family of polypeptides. Cell proliferation and tissue growth

under normal conditions are tightly regulated processes. An intricate system of extracellular and intracellular signalling pathways makes sure that the proliferating cells are not infiltrating into surrounding tissues. Circumventing this control is the hallmark of malignant tumours. It is this contribution to the metastatic property of malignant tumours, which is largely responsible for their lethality (Stetler-Stevenson, W.G. et al., Annu. Rev. Cell Biol. 1993; 9:541-73; Meyer, T. and Hart, I.R., Eur. J Cancer 1998; 34(2):214-21).

Metastasis is a multistage process involving numerous aberrant functions of tumour cells. These include tumour angiogenesis, attachment, adhesion to the vascular basement membrane, local proteolysis, degradation of extracellular matrix components, migration through the vasculature, invasion of the basement membrane, and proliferation at secondary sites (Poste, G. and Fidler, I.J., Nature 1980; 283: 139-146; Liotta, L.A. et al., Cell 1991; 64(2):327-336). Increased proteolytic activity is one documented feature of metastatisizing cells. This increased activity is thought to result from the combined aberrant regulation of extracellular proteolytic enzymes (Chen, W.T., Curr. Opin. Cell Biol. 1992; 4(5): 802-809) in cancer cells as well as in the surrounding stroma.

At the cell-extracellular matrix interface, tumour cells elaborate membrane protrusions termed 'invadopodia' that exhibit increased proteolytic activities at invasion foci and thus allow metastatic cells to digest the surrounding matrix (Chen, W.T., Enzyme Protein 1996; 49:59-71). Perhaps the so far best understood example of such membrane associated protease activity is the involvement of urokinase plasminogen activator and matrix metalloproteinases in some cases of tumour cell migration (DeClerk, Y.A. and Laug, W.E., Enzyme Protein 1996; 49:72-84). Interestingly, it has also been shown that these proteins facilitate the sprouting of blood vessels to feed the growing tumour. (Kroon, M.E. et al., Am. J Pathol. 1999;154(6):1731-42; Rabbani, S.A., In Vivo 1998;12(1):135-42). Accordingly, in animal models it has already been shown that interfering with these proteolytic mechanisms is a valid

approach to treat metastasizing tumours (Wilson, C.L. et al., Proc. Natl Acad. Sci. USA 1997; 94:1402-1407).

Disclosed herein is the identification of a novel extracellular serine  
5 protease (reviewed in Rawlings, N.D. and Barrett, A.J.; Methods Enzymol. 1994: 244:19-61), Seripancrin, specifically over-expressed in certain kinds of tumours, like (but not limited to) colon cancer, ovarian cancer, pancreas cancer, prostate cancer and uterine cancer, or in stromal cells in close proximity to these tumour cells. This protease is a  
10 typical type II transmembrane domain protein with a short cytoplasmic N-terminus which could interact with intracellular components of the cytoskeleton and/or intracellular signalling or degradation pathways. Adjacent to that is a transmembrane domain, immediately followed by a low density lipoprotein (LDL) domain, a scavenger receptor cysteine-rich (SRCR) domain and a protease domain, which based on its sequence  
15 homology identifies this protein as a new member of the class of trypsin-like serine proteases. This domain structure is shared between Seripancrin and its so far closest homologue, the recently cloned type II transmembrane-anchored serine protease TMPRSS2 (Paoloni-Giacobino, A. et al., Genomics 1997; 44(3):309-320). The LDL domain, originally identified as seven tandemly repeated modules in the low density lipoprotein receptor (Südhof, T.C. et al., Science 1985; 228:815-822), is known to contain a calcium binding domain and mediates binding to lipoproteins (Deborah F. et al., Nature 1997; 388:691-693; Russell, D.WQ. et al., J Biol. Chem. 1989; 264:21688-21782). Similarly, the SRCR  
20 domain, originally identified during the analysis of type I macrophage scavenger receptor (Freeman, M. et al., Proc. Natl Acad. Sci. USA 1990; 87:8810-8814), is thought to mediate protein-protein interactions and ligand binding (Hohenester, E. et al., Nat. Struct. Biol. 1999; 6(3):228-232).  
30

This modular structure of Seripancrin suggests that it is a transmembrane serine protease where the LDL and SRCR domains help to define the specificity of Seripancrin's intra- and intermolecular interactions. Although  
35 not yet shown, Seripancrin might be expressed in an inactive form which

then has to be activated first (most likely by a proteolytic mechanism) to become proteolytically active. However, it is also conceivable that the protease inactive form alone can already perform important protein-protein interactions, similar to so-called adaptor proteins which also lack any enzymatic activities. This possibility is supported by the fact that expression of a differentially spliced isoform can be detected for Seripancrin which lacks the proteolytic domain (as well as the SRCR domain). Additionally, cleavage of Seripancrin can result in a secreted form which could function in distance to the Seripancrin expressing cell. Beside these two so far described isoforms there is a third splicing isoform detectable, which represents basically the ORF of the main splicing isoform (AA1-432) plus an additional stretch of 60 amino acids with no obvious sequence homology added at the C-terminus.

Cloning starting point was the identification of a short stretch of cDNA which is overexpressed in pancreas tumour (U54603; Gress, T.M. et al., Genes Chromosomes Cancer 1997; 19(2):97-103). The authors did not disclose any homology for this transcript. Extending this sequence (using standard molecular and biochemical methods) resulted in the identification of the full length form as well as a truncated isoform of this gene which we called Seripancrin. The fact that this gene seems to be specifically upregulated in various cancers, whereas its expression is low up to not detectable in the corresponding healthy tissues, implies that Seripancrin could not only represent a good marker for cancerous tissues, but it could also represent a novel drug target to treat specifically primary and secondary tumours. The gene encoding Seripancrin maps to chromosome 11q22-q23, a locus known to contain cell proliferation and metastasis promoting genes. Interestingly, a cluster of matrix metalloproteases (including MMP-1, MMP-3 and MMP-10; Formstone, C.J. et al., Genomics 1993; 16:289-291) has also been mapped to that region, which could suggest that if there is a correlation between locus and epistatic interaction, Seripancrin is activating or is being activated by any of these MMPs (something similar has been shown for the serine proteases plasmin and trypsin, which have been implicated in the activation of pro-MMP-1 and pro-MMP-3 (Rao C.N. et al., Biochem. Biophys. Res. Commun. 1999; 255(1):94-98 and references therein)).

The biological properties of the Seripancrin are hereinafter referred to as "biological activity of Seripancrin" or "Seripancrin activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of Seripancrin.

5 Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in  
10 which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least  
15 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are biologically active fragments that mediate the biological  
20 activity of Seripancrin, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

25 Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is  
30 often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

35 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from



genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods.. Means for preparing such polypeptides are well understood in the art.

5 In a further aspect, the present invention relates to Seripancrin polynucleotides. Such polynucleotides include:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence selected from SEQ ID NO:1;

10 (b) an isolated polynucleotide comprising the polynucleotide selected from SEQ ID NO:1;

(c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide selected from SEQ ID NO:1;

(d) the isolated polynucleotide selected from SEQ ID NO:1;

15 (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence selected from SEQ ID NO:2;

(f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide selected from SEQ ID NO:2;

20 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence selected from SEQ ID NO:2;

(h) an isolated polynucleotide encoding the polypeptide selected from SEQ ID NO:2;

25 (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence selected from SEQ ID NO:1;

30 (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence selected from SEQ ID NO:2; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or an isolated polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence selected from SEQ ID NO: 1.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding the polypeptide selected from SEQ ID NO:2;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide selected from SEQ ID NO:2;

(c) comprises an RNA transcript of the DNA sequence selected from SEQ ID NO:1; or

(d) is the RNA transcript of the DNA sequence selected from SEQ ID NO:1;

and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences of SEQ ID NO:1 show homology with E13203 (JP 1997149790-A), U75329 (Genomics 1997; 44:309-320). The polynucleotide sequences of SEQ ID NO:1 are cDNA sequences that encode the polypeptides of SEQ ID NO:2. The polynucleotide sequences encoding the polypeptides of SEQ ID NO:2 may be identical to the polypeptides encoding sequences of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptides of SEQ ID NO:2. The polypeptides of the SEQ ID NO:2 are related to other proteins of the serine protease family, having homology and/or structural similarity with pTMPRSS2 (Genomics 1997; 44:302-320)..

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one Seripancrin activity.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human colon, colon tumour, pancreas, pancreas tumour, ovary cancer, prostate cancer, pharynx carcinoma, adenocarcinoma, cheek carcinoma, squamous cell carcinoma, B-cell lymphoma, uterine cancer, testis, fetal lung and embryonic tissues. (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence

is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequences selected from SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a sequence selected from SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having a sequence selected from SEQ ID NO:1 or a fragment thereof, preferably of at least 15 nucleotides.

- 11 -

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such

- 12 -

proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al.* (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the

periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by

- 14 -

hybridizing amplified DNA to labeled Seripancrin nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising Seripancrin polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably a nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;

(b) a nucleotide sequence complementary to that of (a);



- 15 -

(c) a polypeptide of the present invention, preferably a polypeptide of SEQ ID NO:2 or a fragment thereof; or

(d) an antibody to a polypeptide of the present invention, preferably to a polypeptide of SEQ ID NO:2.

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

10 The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has  
15 been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been  
20 mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P.,  
25 (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments  
30 maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of

- 16 -

the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>. The gene of the present invention maps to human chromosome 11q22-q23 (D11S1347-D11S939).

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray hybridisation (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in colon, colon tumour, pancreas, pancreas tumour, ovary cancer, prostate cancer, pharynx carcinoma, adenocarcinoma, cheek carcinoma, squamous cell carcinoma, B-cell lymphoma, uterine cancer, testis, fetal lung and embryonic tissues.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a

- 18 -

vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection).  
5 Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents.  
10 The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation,  
15 such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions  
20 that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that  
25 stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of  
30 chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

35 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the

- 19 -

polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a Seripancrin activity in the mixture, and comparing the Seripancrin activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek et al, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and Seripancrin polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

#### \*Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using

monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

5 A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance,  
10 biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be  
15 used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely  
20 related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

25 Screening methods may also involve the use of transgenic technology and Seripancrin gene. The art of constructing transgenic animals is well established. For example, the Seripancrin gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of  
30 genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the  
35 compound is specific for the human target. Other useful transgenic

- 21 -

animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention;
- or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably selected from SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

## Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original

- 22 -

environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed



monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequences of SEQ ID NO:1..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in

nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps

- 25 -

from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

"% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is

- 26 -

not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

5 Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the  
10 programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the  
15 best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the  
20 algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4  
25 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of  
30 programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) and FASTA (Pearson W R, Methods in  
35 Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448,1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid

- 28 -

deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

$n_a$  is the number of nucleotide or amino acid differences,

$x_a$  is the total number of nucleotides or amino acids in SEQ ID NO:1 or SEQ ID NO:2, respectively,

$I$  is the Identity Index ,

$\cdot$  is the symbol for the multiplication operator, and

in which any non-integer product of  $x_a$  and  $I$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or

- 29 -

polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, unrelated, fused genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-Seripancrin, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-Seripancrin or fragments of -Seripancrin, to improve pharmacokinetic properties of such a fusion protein when used for therapy and to generate a dimeric Seripancrin. The Fc-Seripancrin DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding Seripancrin or fragments thereof. In some uses it would be desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc part completely after expression.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

#### Further examples

##### Example 1

##### Construction of the baculovirus transfer vector and expression

DNA fragment encoding amino acid residues 52-435 of the main splicing isoform was cloned for expression of Seripancrin in the baculovirus expression system. For expression Stratagene's vector pPbac (Stratagene) was used. This system allows expression of a secreted

- 30 -

fusion protein where the signal peptide sequence of the human placental alkaline phosphatase protein is fused in front of the sequence to be expressed. The Seripancrin gene was introduced in frame in this vector via a 5' SmaI restriction site and a 3' BamHI site. A single PCR reaction was carried out using the 5' Primer: 5' AAC CCG GGA AAG GTG ATT CTG GAT AAA TAC TAC 3' and the 3' Primer: 5' AAGGATCC TTA CAG CTC AGC CTT CCA GAC ATT G 3' to amplify the above mentioned region of the main splicing isoform. To check for the maintenance of the correct open reading frame, the complete insert, the insert junctions and the signal peptide sequence provided by the vector was sequenced. Expression of the fusion protein in Sf9 cells was done using standard laboratory methods for baculovirus systems based on expression from the polyhedron locus.

Additional variation of the Seripancrin sequence included in some cases the insertion of an MRGS(H)<sub>6</sub> tag at the 3'-end (C-Terminal) for easier detection of protein expression, purification and concentration.

## Example 2

### Production of Seripancrin

Culture supernatant containing Seripancrin was collected from the baculo expression system and concentrated by pressurized dialysis. A weak anion exchanger such as EMD-DEAE-Fractogel turned out to be ideal for a first adsorption of the protein. Desorption of seripancrin was done by using a linear sodium chloride gradient (0-0.8 M, NaCl, Tris, pH 7.5). Further purification depended mainly on the purity reached in this first chromatographic step. If necessary additional rechromatographies on ion exchanger supports have been conducted. The final step of purification was performed using a Superdex 75 column. The eluted samples have been collected and have been further concentrated by Centricon 10 centrifugation (Amicon) in PBS. These preparations have then been used to perform analytical as well as functional tests. For analytical grade purification of protein - necessary prior to protein sequencing - a reversed phase RP18 column has been used.



- 31 -

Optimization of the chromatographic conditions have been performed using a BiaCore chromatographic system with analytical columns available from Pharmacia. The BiaCore based separation protocol has been scaled up by using FPLC techniques. The optimized running conditions are directly convertible into a semi-preparative or preparative scale of separation. Samples collected from the last chromatographic step have been collected and analysed by SDS-PAGE. Protein bands have been visualized using Coomassie staining. Under reducing conditions the purified recombinant protein revealed a relative molecular weight of 55 kDa  $\pm$  2kDa compared to the calculated theoretical molecular weight of 47962.

Isoelectric focussing using IEF-PAGE (Immobiline 3-10, Pharmacia) technique revealed an isoelectric point of pH 5.7  $\pm$  0.5. Protein bands and IEF-markers have been visualized using Coomassie staining

In some cases a C-terminal histidin tagged version of the recombinant Seripancrin protein has been expressed. The expressed protein was detected by western blotting method using anti-MRGS(H)6 antibody. Purification was performed using chelators such as NTA or imido acetic acid immobilized on a column matrix and modified with metall ions such as Co, Ni, or Cu.

### Example 3

#### Immunization and antibodies

With the purified recombinant protein available, immunization of animals has been started right away. Immune sera were raised in rabbits and high titered reagents were available for further screening.

Additional antisera have been generated by using synthetic peptides deduced from the sequence of the complete protein. Synthetic peptides have been synthesized (amino-acid sequence 15-28, 83-96, 166-180, 246-262, 382-395) coupled to KLH and used for immunization of rabbits. High titered immune sera generated with the recombinant protein or synthetic peptide have been used to established Elisa technology and Western blot technique to monitor and quantitate the recombinant

- 32 -

protein. Generally antibodies of a given specificity have been pooled and precipitated with Ammonium-sulfat and dialysed against PBS. Selected sera have been biotinylated using the NHS-ester derivative of the biotin, available via Pierce. Biotinylation was performed according to the instruction of the manufacturer. The antigens and the immunochemical techniques used to raise and characterize the polyclonal antibodies can easily be combined with protocols used for the production of monoclonal antibody specificities. The expert in the field would make his choice between a classical technique such as the hybridoma based technology ore an antibody library based method according to his local possibilities.

#### Example 4

##### Immuno-Assays for estimation of Seripancrin

Specific sera raised with recombinant seripancrin have been used as a "catcher antibody" for the coating of 96-well micro-titer plates (Nunc). 50 µl of the anti-Seripancrin serum (20 µg/ml) has been used to coat plates over night. Prior to use, the plates have been washed three times with PBS and have been incubated for one hour with a BSA solution (1%) in order to prevent non-specific adhesion. Surplus of blocking solution has been removed and 50 µl Seripancrin has been added in serial delutions and has been incubated for one hour. Plates have been washed three times prior to the application of the biotinylated anti-Seripancrin antibody for detection. After an additional one hour, read-out has been performed via streptavidin-POD catalyzed colour reaction with substrates such as ODB-tablets (Dako) measured at 490 nm.

#### Example 5

##### Protease Activity Assay:

To determine Seripancrin's protease activity, recombinant secreted protein was purified from the supernatant of a baculovirus expression system expressing amino acid 52-435 of the main splicing isoform. The purified protein was added to a buffered solution containing a universal protease substrate (casein, resorufin-labeled; BOEHRINGER MANNHEIM) according to the manufacturer's protocol.

**Claims**

1. An isolated polypeptide selected from one of the groups consisting of:
  - (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;
  - 5 (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;
  - c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and
  - d) the polypeptide sequence of SEQ ID NO:2 and
  - 10 (e) fragments and variants of such polypeptides in (a) to (d).
2. The isolated polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2.
- 15 3. The isolated polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2.
4. An isolated polynucleotide selected from one of the groups consisting of:
  - (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;
  - 20 (b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;
  - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;
  - 25 (d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

- 34 -

(e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;

5 (f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

or a polynucleotide sequence complementary to said isolated polynucleotide

and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

10

5. An isolated polynucleotide as claimed in claim 4 selected from the group consisting of:

(a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(b) the isolated polynucleotide of SEQ ID NO:1;

15 (c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and

(d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

20 6. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

25

8. A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the

production of said polypeptide and recovering the polypeptide from the culture medium.

9. A fusion protein consisting of the Immunoglobulin Fc-region and any one  
5 polypeptide of claim 1.

10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:

10 (a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

15 (b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;

20 (d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

25 (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

(f) producing said compound according to biotechnological or chemical standard techniques.

## SEQUENCE LISTING

&lt;110&gt; Merck Patent GmbH

5 &lt;120&gt; Seripancrin

&lt;130&gt; SeripancrinUHWS

&lt;140&gt;

10 &lt;141&gt;

&lt;160&gt; 6

&lt;170&gt; PatentIn Ver. 2.1

15

&lt;210&gt; 1

&lt;211&gt; 1305

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

20

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1305)

25 &lt;400&gt; 1

atg gat cct gac agt gat caa cct ctg aac agc ctc gat gtc aaa ccc 48  
 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
           1                          5                          10                          15

30 ctg cgc aaa ccc cgt atc ccc atg gag acc ttc aga aag gtg ggg atc 96  
 Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile  
                           20                          25                          30

35 ccc atc atc ata gca cta ctg agc ctg gcg agt atc atc att gtg gtt 144  
 Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
                           35                          40                          45

40 gtc ctc atc aag gtg att ctg gat aaa tac tac ttc ctc tgc ggg cag 192  
 Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln  
                           50                          55                          60

45 cct ctc cac ttc atc ccg agg aag cag ctg tgt gac gga gag ctg gac 240  
 Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp  
                           65                          70                          75                          80

50 tgt ccc ttg ggg gag gac gag gag cac tgt gtc aag agc ttc ccc gaa 288  
 Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
                           25                          30                          35                          40

55 ggg cct gca gtg gca gtc cgc ctc tcc aag gac cga tcc aca ctg cag 336  
 Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln  
                           100                          105                          110

60 gtg ctg gac tgg gcc aca ggg aac tgg ttc tct gcc tgt ttc gac aac 384  
 Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
                           115                          120                          125

65 ttc aca gaa gct ctc gct gag aca gcc tgt agg cag atg ggc tac agc 432  
 Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser  
                           130                          135                          140

acc aaa ccc act ttc aga gct gtg gag att ggc cca gac cag gat ctg 460  
 Ser Lys Pro Thr Phe Arg Ala Val Glu Ile Gly Pro Asp Gln Asp Leu  
 145 150 155 160

5 gat gtt gtt gaa atc aca gaa aac agc cag gag ctt cgc atg cgg aac 528  
 Asp Val Val Glu Ile Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn  
 165 170 175

10 tca agt ggg ccc tgt ctc tca ggc tcc ctg gtc tcc ctg cac tgt ctt 576  
 Ser Ser Gly Pro Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu  
 180 185 190

15 gcc tgt ggg aag agc ctg aag acc ccc cgt gtg gtg ggt ggg gag gag 624  
 Ala Cys Gly Lys Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu  
 195 200 205

20 gcc tct gtg gat tct tgg cct tgg cag gtc agc atc cag tac gac aaa 672  
 Ala Ser Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys  
 210 215 220

25 cag cac gtc tgt gga ggg agc atc ctg gac ccc cac tcg gtc ctc acg 720  
 Gln His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr  
 225 230 235 240

gca gcc cac tgc ttc agg aaa cat acc gat gtg ttc aac tgg aag gtg 768  
 Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys Val  
 245 250 255

30 cgg gca ggc tca gac aaa ctg ggc agc ttc cca tcc ctg gct gtg gcc 816  
 Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala  
 260 265 270

35 aag atc atc atc att gaa ttc aac ccc atg tac ccc aaa gac aat gac 864  
 Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp  
 275 280 285

40 atc gcc ctc atg aag ctg cag ttc cca ctc act ttc tca ggc aca gtc 912  
 Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val  
 290 295 300

agg ccc atc tgt ctg ccc ttc ttt gat gag gag ctc act cca gcc acc 960  
 Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu Leu Thr Pro Ala Thr  
 305 310 315 320

45 cca ctc tgg atc att gga tgg ggc ttt acg aag cag aat gga ggg aag 1008  
 Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys  
 325 330 335

50 atg tct gac ata ctg ctg cag gcg tca gtc cag gtc att gac agc aca 1056  
 Met Ser Asp Ile Leu Leu Gln Ala Ser Val Gln Val Ile Asp Ser Thr  
 340 345 350

55 cgg tgc aat gca gac gat gcg tac cag ggg gaa gtc acc gag aag atg 1104  
 Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Glu Val Thr Glu Lys Met  
 355 360 365

60 atg tgt gca ggc atc ccg gaa ggg ggt gtg gac acc tgc cag ggt gac 1152  
 Met Cys Ala Gly Ile Pro Glu Gly Gly Val Asp Thr Cys Gln Gly Asp  
 370 375 380

```

    agt ggt ggg ccc ctg atg tac caa tct gac cag tgg cat gtg gtg ggc      1200
    Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly
    385                               390                               395                               400

5   atc gtt acc tgg ggc tat ggc tgc ggc ggc ccc agc acc cca gga gta      1248
    Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val
                                405                               410                               415

    tac acc aag gtc tca gcc tat ctg aac tgg atc tac aat gtc tgg aag      1296
    Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys
                                420                               425                               430

    gct gag ctg
    Ala Glu Leu
15   435

    <210> 2
    <211> 435
20   <212> PRT
    <213> Homo sapiens

    <400> 2
    Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro
25   1                               5                               10                               15

    Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile
                                20                               25                               30

30   Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val
                                35                               40                               45

    Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln
    50                               55                               60

35   Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp
    65                               70                               75                               80

    Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu
40   85                               90                               95

    Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln
                                100                               105                               110

45   Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn
    115                               120                               125

    Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser
    130                               135                               140

50   Ser Lys Pro Thr Phe Arg Ala Val Glu Ile Gly Pro Asp Gln Asp Leu
    145                               150                               155                               160

    Asp Val Val Glu Ile Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn
55   165                               170                               175

    Ser Ser Gly Pro Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu
                                180                               185                               190

60   Ala Cys Gly Lys Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu
    195                               200                               205

```



Ala Ser Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys  
 210 215 220  
 5 Gln His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr  
 225 230 235 240  
 Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys Val  
 245 250 255  
 10 Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala  
 260 265 270  
 Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp  
 275 280 285  
 Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val  
 290 295 300  
 20 Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu Leu Thr Pro Ala Thr  
 305 310 315 320  
 Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys  
 325 330 335  
 25 Met Ser Asp Ile Leu Leu Gln Ala Ser Val Gln Val Ile Asp Ser Thr  
 340 345 350  
 Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Glu Val Thr Glu Lys Met  
 355 360 365  
 Met Cys Ala Gly Ile Pro Glu Gly Gly Val Asp Thr Cys Gln Gly Asp  
 370 375 380  
 35 Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly  
 385 390 395 400  
 Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val  
 405 410 415  
 40 Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys  
 420 425 430  
 Ala Glu Leu  
 45 435  
 <210> 3  
 50 <211> 1479  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 55 <221> CDS  
 <222> (1)..(1479)  
 <400> 3  
 atg gat cct gac agt gat daa cct ctg aac agc ctc gat gtc aaa ccc 48  
 60 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
 1 5 10 15

	ctg	agg	aaa	ccc	cgt	atc	ccc	atg	gag	acc	ttc	aga	aag	gtg	ggg	atc	96
	Leu	Arg	Lys	Pro	Arg	Ile	Pro	Met	Glu	Thr	Phe	Arg	Lys	Val	Gly	Ile	
				20					25					30			
5	ccc	atc	atc	ata	gca	cta	ctg	agc	ctg	gcg	agt	atc	atc	att	gtg	gtt	144
	Pro	Ile	Ile	Ile	Ala	Leu	Leu	Ser	Leu	Ala	Ser	Ile	Ile	Ile	Val	Val	
			35					40					45				
10	gtc	ctc	atc	aag	gtg	att	ctg	gat	aaa	tac	tac	ttc	ctc	tgc	ggg	cag	192
	Val	Leu	Ile	Lys	Val	Ile	Leu	Asp	Lys	Tyr	Tyr	Phe	Leu	Cys	Gly	Gln	
		50					55					60					
15	cct	ctc	cac	ttc	atc	ccg	agg	aag	cag	ctg	tgt	gac	gga	gag	ctg	gac	240
	Pro	Leu	His	Phe	Ile	Pro	Arg	Lys	Gln	Leu	Cys	Asp	Gly	Glu	Leu	Asp	
	65					70					75					80	
20	tgt	ccc	tgg	ggg	gag	gac	gag	gag	cac	tgt	gtc	aag	agc	ttc	ccc	gaa	288
	Cys	Pro	Leu	Gly	Glu	Asp	Glu	Glu	His	Cys	Val	Lys	Ser	Phe	Pro	Glu	
					95					90					95		
25	ggg	ccc	gca	gtg	gca	gtc	cgc	ctc	tcc	aag	gac	cga	tcc	aca	ctg	cag	336
	Gly	Pro	Ala	Val	Ala	Val	Arg	Leu	Ser	Lys	Asp	Arg	Ser	Thr	Leu	Gln	
			100					105						110			
30	gtg	ctg	gac	tgg	gcc	aca	ggg	aac	tgg	ttc	tct	gcc	tgt	ttc	gac	aac	384
	Val	Leu	Asp	Ser	Ala	Thr	Gly	Asn	Trp	Phe	Ser	Ala	Cys	Phe	Asp	Asn	
			115					120					125				
35	ttc	aca	gaa	ggt	ctc	gct	gag	aca	gcc	tgt	agg	cag	atg	ggc	tac	agc	432
	Phe	Thr	Glu	Ala	Leu	Ala	Glu	Thr	Ala	Cys	Arg	Gln	Met	Gly	Tyr	Ser	
		130					135					140					
40	agc	aaa	ccc	act	ttc	aga	gct	gtg	gag	att	ggc	cca	gac	cag	gat	ctg	480
	Ser	Lys	Pro	Thr	Phe	Arg	Ala	Val	Glu	Ile	Gly	Pro	Asp	Gln	Asp	Leu	
	145					150					155					160	
45	gat	gtt	gtt	gaa	atc	aca	gaa	aac	agc	cag	gag	ctt	cgc	atg	cgg	aac	528
	Asp	Val	Val	Glu	Ile	Thr	Glu	Asn	Ser	Gln	Glu	Leu	Arg	Met	Arg	Asn	
					165					170					175		
50	tca	agt	ggg	ccc	tgt	ctc	tca	ggc	tcc	ctg	gtc	tcc	ctg	cac	tgt	ctt	576
	Ser	Ser	Gly	Pro	Cys	Leu	Ser	Gly	Ser	Leu	Val	Ser	Leu	His	Cys	Leu	
				180					195					190			
55	gcc	tgt	ggg	aag	agc	ctg	aag	acc	ccc	cgt	gtg	gtg	ggt	ggg	gag	gag	624
	Ala	Cys	Gly	Lys	Ser	Leu	Lys	Thr	Pro	Arg	Val	Val	Gly	Gly	Glu	Glu	
			195					200					205				
60	gcc	tct	gtg	gat	tct	tgg	cct	tgg	cag	gtc	agc	atc	cag	tac	gac	aaa	672
	Ala	Ser	Val	Asp	Ser	Trp	Pro	Trp	Gln	Val	Ser	Ile	Gln	Tyr	Asp	Lys	
		210					215						220				
65	cag	cac	gtc	tgt	gga	ggg	agc	atc	ctg	gac	ccc	cac	tgg	gtc	ctc	acg	720
	Gln	His	Val	Cys	Gly	Gly	Ser	Ile	Leu	Asp	Pro	His	Trp	Val	Leu	Thr	
	225					230					235					240	
70	gca	ggc	cac	tgc	ttc	agg	aaa	cat	acc	gat	gtg	ttc	aac	tgg	aag	gtg	768
	Ala	Ala	His	Cys	Phe	Arg	Lys	His	Thr	Asp	Val	Phe	Asn	Trp	Lys	Val	
					245					250					255		

cgg gca ggc tca gac aaa ctg ggc agc ttc cca tcc ctg gct gtg gcc 816  
 Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala  
 260 265 270

5 aag atc atc atc att gaa ttc aac ccc atg tac ccc aaa gac aat gac 864  
 Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp  
 275 280 285

10 atc gcc ctc atg aag ctg cag ttc cca ctc act ttc tca ggc aca gtc 912  
 Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val  
 290 295 300

15 agg ccc atc tgt ctg ccc ttc ttt gat gag gag ctc act cca gcc acc 960  
 Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu Leu Thr Pro Ala Thr  
 305 310 315 320

20 cca ctc tcg atc att gga tgg ggc ttt acg aag cag aat gga ggg aag 1008  
 Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys  
 325 330 335

atg tct gac ata ctg ctg cag gcg tca gtc cag gtc att gac agc aca 1056  
 Met Ser Asp Ile Leu Leu Gln Ala Ser Val Gln Val Ile Asp Ser Thr  
 340 345 350

25 cgg tgc aat gca gac gat gcg tac cag ggg gaa gtc acc gag aag atg 1104  
 Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Glu Val Thr Glu Lys Met  
 355 360 365

30 atg tgt gca ggc atc ccg gaa ggg ggt gtg gac acc tgc cag ggt gac 1152  
 Met Cys Ala Gly Ile Pro Glu Gly Gly Val Asp Thr Cys Gln Gly Asp  
 370 375 380

35 agt ggt ggg ccc ctg atg tac caa tct gac cag tgg cat gtg gtg ggc 1200  
 Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly  
 385 390 395 400

40 atc gtt agc tgg ggc tat ggc tgc ggg ggc ccg agc acc cca gga gta 1248  
 Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val  
 405 410 415

tac acc aag gtc tca gcc tat ctc aac tgg atc tac aat gtc tgg aag 1296  
 Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys  
 420 425 430

45 gat aga act att cag aga agc tgt aac tcc cca ggg aca ggt ctt gtg 1344  
 Asp Arg Thr Ile Gln Arg Ser Cys Asn Ser Pro Gly Thr Gly Leu Val  
 435 440 445

50 att cag caa cca gct gta ccg ctg atg gag cta cgg tca gct cgg cac 1392  
 Ile Gln Gln Pro Ala Val Pro Leu Met Glu Leu Arg Ser Ala Arg His  
 450 455 460

55 aca cat cgc ctg acc acc tgt gtt tgc ttt ctc tca ttc cct gcc tta 1440  
 Thr His Arg Leu Thr Thr Cys Val Cys Phe Leu Ser Phe Pro Ala Leu  
 465 470 475 480

cag ccc ctg tcc ccc tta tgc cca ttt ccc tgg gat tga 1479  
 Gln Pro Leu Ser Pro Leu Cys Pro Phe Pro Trp Asp  
 485 490

60

<210> 4  
 <211> 492  
 <212> PRT  
 <213> Homo sapiens

5  
 <400> 4  
 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
 1 5 10 15  
 10 Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile  
 20 25 30  
 Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
 35 40 45  
 Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln  
 50 55 60  
 15 Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp  
 65 70 75 80  
 Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
 85 90 95  
 Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln  
 100 105 110  
 20 Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
 115 120 125  
 Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser  
 130 135 140  
 25 Ser Lys Pro Thr Phe Arg Ala Val Glu Ile Gly Pro Asp Gln Asp Leu  
 145 150 155 160  
 Asp Val Val Glu Ile Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn  
 165 170 175  
 30 Ser Ser Gly Pro Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu  
 180 185 190  
 Ala Cys Gly Lys Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu  
 195 200 205  
 Ala Ser Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys  
 210 215 220  
 35 Gln His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr  
 225 230 235 240  
 Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys Val  
 245 250 255  
 40 Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala  
 260 265 270  
 Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp  
 275 280 285  
 Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val  
 290 295 300  
 45 Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu Leu Thr Pro Ala Thr  
 305 310 315 320  
 Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys  
 325 330 335  
 50 Met Ser Asp Ile Leu Leu Gln Ala Ser Val Gln Val Ile Asp Ser Thr  
 340 345 350  
 Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Glu Val Thr Glu Lys Met  
 355 360 365  
 Met Cys Ala Gly Ile Pro Glu Gly Gly Val Asp Thr Cys Gln Gly Asp  
 370 375 380  
 55 Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly  
 385 390 395 400  
 Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val  
 405 410 415  
 Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys  
 420 425 430  
 60 Asp Arg Thr Ile Gln Arg Ser Cys Asn Ser Pro Gly Thr Gly Leu Val

```

      435              440              445
Ile Gln Gln Pro Ala Val Pro Leu Met Glu Leu Arg Ser Ala Arg His
      450              455              460
Thr His Arg Leu Thr Thr Cys Val Cys Phe Leu Ser Phe Pro Ala Leu
5  465              470              475              480
Gln Pro Leu Ser Pro Leu Cys Pro Phe Pro Trp Asp
      485              490

10
<210> 5
<211> 609
<212> DNA
<213> Homo sapiens

15
<220>
<221> CDS
<222> (1)...(609)

20
<400> 5
atg gat cct gac agt gat caa cct ctg aac agc ctc gat gtc aaa ccc 48
Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro
      1              5              10              15

25
ctg cgc aaa ccc cgt atc ccc atg gag acc ttc aga aag gtg ggg atc 96
Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile
      20              25              30

30
ccc atc atc ata gca cta ctg agc ctg gcg agt atc atc att gtg gtt 144
Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val
      35              40              45

35
gtc ctc atc aag gtg att ctg gat aaa tac tac ttc ctc tgc ggg cag 192
Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln
      50              55              60

40
cct ctc cac ttc atc ccg agg aag cag ctg tgt gac gga gag ctg gac 240
Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp
      65              70              75              80

45
tgt ccc ttg ggg gag gac gag gag cac tgt gtc aag agc ttc ccc gaa 288
Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu
      85              90              95

50
ggg cct gca gtg gca gtc cgc ctc tcc aag gac cga tcc aca ctg cag 336
Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln
      100              105              110

55
gtg ctg gac tgg gcc aca ggg aac tgg ttc tct gcc tgt ttc gac aac 384
Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn
      115              120              125

60
ttc aca gca gcc cta gct cgg cca cac ttg gtg ctc cca gca tcc cag 432
Phe Thr Ala Ala Leu Ala Arg Pro His Leu Val Leu Pro Ala Ser Gln
      130              135              140

65
gga gag aca gag ccc act gaa caa ggt ctc agg ggt att gct aag cca 480
Gly Glu Thr Gln Pro Thr Glu Gln Gly Leu Arg Gly Ile Ala Lys Pro
      145              150              155              160

70
aga agg aac ttt ccc aca cta ctg aat gga agc agg ctg tct tgt aaa 528

```

Arg Arg Asn Phe Pro Thr Leu Leu Asn Gly Ser Arg Leu Ser Cys Lys  
 165 170 175  
 agc cca gat cac tgt ggg ctg gag agc aga agg aaa ggg tct gcg cca 576  
 5 Ser Pro Asp His Cys Gly Leu Glu Arg Arg Arg Lys Gly Ser Ala Pro  
 180 185 190  
 gcc ctg tcc gtc ttc acc cat ccc caa gcc tac 609  
 10 Ala Leu Ser Val Phe Thr His Pro Gln Ala Tyr  
 195 200  
 <210> 6  
 <211> 203  
 15 <212> PRT  
 <213> Homo sapiens  
 <400> 6  
 20 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
 1 5 10 15  
 Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile  
 20 25 30  
 25 Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
 35 40 45  
 Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln  
 50 55 60  
 30 Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp  
 65 70 75 80  
 Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
 35 85 90 95  
 Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln  
 100 105 110  
 40 Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
 115 120 125  
 Phe Thr Ala Ala Leu Ala Arg Pro His Leu Val Leu Pro Ala Ser Gln  
 130 135 140  
 45 Gly Glu Thr Gln Pro Thr Glu Gln Gly Leu Arg Gly Ile Ala Lys Pro  
 145 150 155 160  
 Arg Arg Asn Phe Pro Thr Leu Leu Asn Gly Ser Arg Leu Ser Cys Lys  
 50 165 170 175  
 Ser Pro Asp His Cys Gly Leu Glu Arg Arg Arg Lys Gly Ser Ala Pro  
 180 185 190  
 55 Ala Leu Ser Val Phe Thr His Pro Gln Ala Tyr  
 195 200

## SEQUENCE LISTING

&lt;110&gt; M. rek. Pat. nt. GmbH

5 &lt;120&gt; Seripancorin

&lt;130&gt; SeripancorinDHWS

&lt;140&gt;

10 &lt;141&gt;

&lt;160&gt; 6

&lt;170&gt; PatentIn Ver. 2.1

15

&lt;210&gt; 1

&lt;211&gt; 1305

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

20

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1305)

25 &lt;400&gt; 1

atg ggt cct gac agt gat ccc cct ctg aac agc ctc gat gtc aca ccc 48  
Met Arg Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
1 5 10 15

30 ctg cgc aca ccc cgt atc ccc atg gag acc ttc aga ang gtc gag aac 96  
Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile  
20 25 30

35 ccc atc atc ata gca cta ctg agc ctg gag agt atc atc att gtc gtc 144  
Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
35 40 45

40 gtc ctc atc aag gtc att ctg gat aac tac taa ttc ctc tgc ggc cag 192  
Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln  
50 55 60

45 cct ctc cac ttc ala cag agg aag ccc ctg tgt gac gga gag ctg gac 240  
Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp  
65 70 75 80

50 tgt ccc ttg gag gag gac gag gag cac tgt gtc aag agc ttc ccc gag 288  
Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
85 90 95

55 gag ccc gca gtc gca gtc cgc ctc tcc aag gac cga tcc acc ctg cag 336  
Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln  
100 105 110

60 gtc ctg gac tgg ggc aca ggg aac tgg ttc tct gcc tgt ttc gac aac 384  
Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
115 120 125

65 ttc aca ggc gct ctc gct gag aca gcc tgt aag cag atg gcc tac agc 432  
Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser  
130 135 140

	agc	aaa	ccc	act	ttc	aga	gct	gtg	gag	att	ggc	cca	gac	gag	gat	ctg	480
	Ser	Lys	Pro	Thr	Phe	Arg	Ala	Val	Glu	Ile	Gly	Pro	Asp	Gln	Asp	Leu	
	155					150					155					160	
5	ggt	glt	glt	gaa	acc	acc	gag	anc	agc	cag	gag	ctt	ggc	atg	egg	aac	528
	Asp	Val	Val	Glu	Ile	Thr	Gln	Asn	Ser	Gln	Glu	Leu	Arg	Met	Arg	Asn	
					165					170					175		
10	tca	agt	ggg	ccc	tgt	ctc	tca	ggc	tcc	ctg	gtc	tcc	ctg	cac	tgt	ctt	576
	Ser	Ser	Gly	Pro	Cys	Leu	Ser	Gly	Ser	Leu	Val	Ser	Leu	His	Cys	Leu	
				180				185						190			
15	gac	tgt	ggg	aaa	acc	ctg	gag	acc	ccc	cat	gtg	gtg	ggt	ggg	gag	gag	624
	Ala	Cys	Gly	Lys	Ser	Leu	Lys	Thr	Pro	Arg	Val	Val	Gly	Gly	Glu	Glu	
			195					200					205				
20	gac	act	gtg	gac	tgt	tgg	cat	tgg	cag	gtc	agc	atc	cag	tac	gac	aaa	672
	Ala	Ser	Val	Asp	Ser	Trp	Pro	Trp	Gln	Val	Ser	Ile	Gln	Tyr	Asp	Lys	
		210				215						220					
25	cag	cac	gtc	tgt	gaa	gag	gag	ctg	ctg	gac	ccc	cac	tgg	gtc	ctc	acc	720
	Gln	His	Val	Cys	Gly	Gly	Ser	Ile	Leu	Asp	Pro	His	Trp	Val	Leu	Thr	
	225				230					235					240		
30	gca	gcc	cac	tgc	ttc	ggn	aaa	gat	acc	gat	gtg	ttc	aac	tgg	aag	gtg	768
	Ala	Ala	His	Cys	Phe	Arg	Lys	His	Thr	Asp	Val	Phe	Asn	Trp	Lys	Val	
				245				250						255			
35	egg	gca	ggc	tca	gac	aaa	ctg	ggc	agc	ttc	cca	tcc	ctg	gct	gtg	gcc	816
	Arg	Ala	Gly	Ser	Asp	Lys	Leu	Gly	Ser	Phe	Pro	Ser	Leu	Ala	Val	Ala	
				260				265						270			
40	aat	atc	atc	atc	aaa	gaa	ttc	aac	ccc	atg	cac	ccc	gno	gac	aat	gac	864
	Lys	Ile	Ile	Ile	Ile	Glu	Phe	Asn	Pro	Met	Tyr	Pro	Lys	Asp	Asn	Asp	
		275						280					285				
45	atc	gac	ctc	atg	gag	ctg	gag	ttc	cca	ctc	acc	tcc	tca	ggt	acn	gtc	912
	Ile	Ala	Leu	Met	Lys	Leu	Gln	Phe	Pro	Leu	Thr	Phe	Ser	Gly	Thr	Val	
		290					295						300				
50	agg	ccc	atc	tat	ctg	ccc	ttc	ttt	gat	gag	gag	ctc	acc	cca	gcc	acc	960
	Arg	Pro	Ile	Cys	Leu	Pro	Phe	Phe	Asp	Glu	Glu	Leu	Thr	Pro	Ala	Thr	
	305					310				315					320		
55	cca	ctc	tgg	acc	att	gga	tgg	ggc	ttt	atg	aag	cag	gat	ggg	gga	gag	1008
	Pro	Leu	Trp	Ile	Ile	Gly	Trp	Gly	Phe	Thr	Lys	Gln	Asn	Gly	Gly	Lys	
					325			330						335			
60	atg	tgt	gac	ala	ctg	ctg	cag	ggg	tca	gtc	cag	ctc	att	gac	agc	aca	1056
	Met	Ser	Asp	Ile	Leu	Leu	Gln	Ala	Ser	Val	Gln	Val	Ile	Asp	Ser	Thr	
				340			345						350				
65	egg	tgc	aat	gaa	gac	gat	ggg	tac	cag	ggg	gaa	gtc	acc	gag	aag	atg	1104
	Arg	Cys	Asn	Ala	Asp	Asp	Ala	Tyr	Gln	Gly	Glu	Val	Thr	Glu	Lys	Met	
			355				360						365				
70	atg	tgt	gca	ggc	atc	ccg	gaa	ggg	ggt	gtg	gac	acc	tgc	cag	ggt	gac	1152
	Met	Cys	Ala	Gly	Ile	Pro	Glu	Gly	Gly	Val	Asp	Thr	Cys	Gln	Gly	Asp	
		370				375				380							



agl ggl ggg ggc ggg ggg tac caa cct gag cag tgg cat gln gtr ggc 1200  
 Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly  
 385 390 395 400

5 atc gtc acc tgg ggc tac ggt tgc ggc ggc ggc ggc acc cca gga gta 1205  
 Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val  
 405 410 415

10 ttc acc gag gtc tca gcc tac ttc aac tgg acc ttc ttc gtc tgg aag 1210  
 Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys  
 420 425 430

gcc gag cgc  
 Ala Glu Leu 1305  
 15 435

<210> 1  
 <211> 488  
 20 <212> PAT  
 <213> Homo sapiens

<400> 2  
 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
 25 5 10 15

Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile  
 20 25 30

30 Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
 35 40 45

Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln  
 50 55 60

35 Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp  
 65 70 75 80

40 Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
 85 90 95

Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln  
 100 105 110

45 Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
 115 120 125

Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser  
 130 135 140

50 Ser Lys Pro Thr Phe Arg Ala Val Glu Ile Gly Pro Asp Gln Asp Leu  
 145 150 155 160

Asp Val Val Glu Ile Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn  
 165 170 175

Ser Ser Gly Pro Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu  
 180 185 190

60 Ala Cys Gly Lys Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu  
 195 200 205

Ala Ser Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys  
 210 215 220  
 5 Gln His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr  
 225 230 235 240  
 Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys Val  
 245 250 255  
 10 Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala  
 260 265 270  
 Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp  
 275 280 285  
 15 Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val  
 290 295 300  
 20 Arg Pro Ile Cys Leu Pro Phe Phe Asp Gln Gln Leu Thr Pro Ala Thr  
 305 310 315 320  
 Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys  
 325 330 335  
 25 Met Ser Asp Ile Leu Leu His Ala Ser Val Gln Val Ile Asp Ser Thr  
 340 345 350  
 Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Gln Val Thr Gln Lys Met  
 355 360 365  
 30 Met Cys Ala Gly Ile Pro Gln Gly Gly Val Asp Thr Cys Gln Gly Asp  
 370 375 380  
 35 Ser Gly Gly Pro Leu Met Tyr Gln Ser Asn Gln Trp His Val Val Gly  
 385 390 395 400  
 Tie Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val  
 405 410 415  
 40 Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys  
 420 425 430  
 45 Ala Gln Leu  
 435  
 50 <210> 3  
 <211> 1479  
 <212> DNA  
 <213> Homo sapiens  
 55 <220>  
 <221> CDS  
 <222> {1}...{1479}  
 60 <400> 3  
 atg gat cct gac agt gat caa cct ctg aac agc ctc gat gtc aac ccc 48  
 Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro  
 10 15

	ctg cgt aaa ccc cgt atc acc atg gag acc ttc aqa aag gtg ggg atc	96
	Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile	
	20 25 30	
5	ccc acc atc ata gaa cta cgg agc cgc ggc wgt ala acc att gtg gtc	124
	Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val	
	35 40 45	
10	gtc ctt atc aag ggc att ctg gat aaa tac tac ttc ctc tgc agg cag	132
	Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Gln	
	50 55 60	
15	ccc ctc ccc ttc atc cgg agg aag cag ctg cgt gac gga gag ctc gag	240
	Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asp Gly Glu Leu Asp	
	65 70 75 80	
20	tgt ctt ttg ggg gag gac gag gag ccc tgt gtc aag agc ttc ccc gaa	288
	Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu	
	85 90 95	
25	ggg ctt gaa ggc gaa gtc agc acc tcc aag gac tga tcc acc tgc cag	336
	Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln	
	100 105 110	
30	gtg ctg gac tgc gnc aca ggg aac tgg ttc tct gcc tgt ttc gac aac	384
	Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn	
	115 120 125	
35	ttc acc gaa ggt ccc gct gag aca gcc tgt agc cag atg ggc tac agc	432
	Phe Thr Glu Ala Leu Ala Glu Thr Ala Cys Arg Gln Met Gly Tyr Ser	
	130 135 140	
40	agc aaa ccc act ttc aga gct gtg gag att ggc cca gac cag gat atg	480
	Ser Lys Pro Thr Phe Arg Ala Val Glu Ile Gly Pro Asp Gln Asp Leu	
	145 150 155 160	
45	gat gtt gtt gaa atc aca gaa aac atc cag gag att cgc atg cgg aac	528
	Asp Val Val Glu Ile Thr Glu Asn Ser Gln Glu Leu Arg Met Arg Asn	
	165 170 175	
50	tca agt ggg ccc tgt ctc tca ggc tcc ctg gtc tcc ctg cac tgt att	576
	Ser Ser Gly Pro Cys Leu Ser Gly Ser Leu Val Ser Leu His Cys Leu	
	180 185 190	
55	gcc tct ggg aag agc ctg aag acc ccc cct gtc gtc ggt ggg gag gag	624
	Ala Cys Gly Lys Ser Leu Lys Thr Pro Arg Val Val Gly Gly Glu Glu	
	195 200 205	
60	gcc tct gtg gat tct tgg cct tgg cag gtc agc att cag tcc gac aaa	672
	Ala Ser Val Asp Ser Trp Pro Trp Gln Val Ser Ile Gln Tyr Asp Lys	
	210 215 220	
65	cag ccc ctg tgt gga ggg agc ala ctg gac ccc ccc cgg gtc ctc acg	720
	Gln His Val Cys Gly Gly Ser Ile Leu Asp Pro His Trp Val Leu Thr	
	225 230 235 240	
70	gaa gaa ccc tgc ttc agg aac cat acc gat gtc ttc aac tgg aag gtc	768
	Ala Ala His Cys Phe Arg Lys His Thr Asp Val Phe Asn Trp Lys Val	
	245 250 255	

	cgc gca gcc tca gac aaa ctg ggc agc ttc cca lnc ctg ggt gtc ggc	816
	Arg Ala Gly Ser Asp Lys Leu Gly Ser Phe Pro Ser Leu Ala Val Ala	
	260 265 270	
5	aaq alc alc alc alc gaa ttc ccc atg tac ccc aaa gac aac gac	864
	Lys Ile Ile Ile Ile Glu Phe Asn Pro Met Tyr Pro Lys Asp Asn Asp	
	275 280 285	
10	atc gcc ctg atg aaq ctg cag ttc cca ctg act ttc cca gcc aca gtc	912
	Ile Ala Leu Met Lys Leu Gln Phe Pro Leu Thr Phe Ser Gly Thr Val	
	290 295 300	
15	agg ccc aac tgl cag ccc lnc ttt gat aaq aaq ccc act cca gcc acc	960
	Arg Pro Ile Cys Leu Pro Phe Phe Asp Glu Glu Leu Thr Pro Ala Thr	
	305 310 315 320	
20	cca ctg tgg atc aac gga lnc ggc ttt ccc aaq cag act gga gga aaq	1008
	Pro Leu Trp Ile Ile Gly Trp Gly Phe Thr Lys Gln Asn Gly Gly Lys	
	325 330 335	
25	atg tct gac ala ctg ctg cag ggc cca gtc cag gtc att gac aac aac	1056
	Met Ser Asp Ile Leu Leu Gln Ala Ser Val Gln Val Ile Asp Ser Thr	
	340 345 350	
30	egg tgc aat gcc gac gat aaq tcc cca gga gaa gtc acc gac aaq atg	1104
	Arg Cys Asn Ala Asp Asp Ala Tyr Gln Gly Glu Val Thr Glu Lys Met	
	355 360 365	
35	atg tgt gca gcc atc ccg gaa ggg ggt gtc ccc acc lnc cag ggt gac	1152
	Met Cys Ala Gly Ile Pro Glu Gly Gly Val Asp Thr Cys Gln Gly Asp	
	370 375 380	
40	agt ggt gga ccc ctg atg tac cca tct gac cag tgg cat gtc gtc ggc	1200
	Ser Gly Gly Pro Leu Met Tyr Gln Ser Asp Gln Trp His Val Val Gly	
	385 390 395 400	
45	atc gat agc tgg gga tct ggc tcc ggc ccc agc acc cca gga gca	1248
	Ile Val Ser Trp Gly Tyr Gly Cys Gly Gly Pro Ser Thr Pro Gly Val	
	405 410 415	
50	lnc acc aag gtc tca gcc cat ctg acc tgg atc tac aat gtc tgg aag	1296
	Tyr Thr Lys Val Ser Ala Tyr Leu Asn Trp Ile Tyr Asn Val Trp Lys	
	420 425 430	
55	gat aga act att cag aga agc tgt aac tcc cca gaa ata gat att ggc	1344
	Asp Arg Thr Ile Gln Arg Ser Cys Asn Ser Pro Gly Thr Gly Leu Val	
	435 440 445	
60	all cag caa cca gcc gta ccg ctg atg gac cca egg tca gct cgg aac	1392
	Ile Gln Gln Pro Ala Val Pro Leu Met Glu Leu Arg Ser Ala Arg His	
	450 455 460	
65	aca cat cgc atg acc acc tgt gtt tgc ttt ctg tca ttc cct gcc tta	1440
	Thr His Arg Leu Thr Thr Cys Val Cys Phe Leu Ser Phe Pro Ala Leu	
	465 470 475 480	
70	cag ccc ctg tcc ccc tta tgc ccc ttt ccc tgg gat tga	1479
	Gln Pro Leu Ser Pro Leu Cys Pro Phe Pro Trp Asp	
	485 490	

<210> 4  
 <211> 492  
 <212> PRT  
 <213> Homo sapiens

5

&lt;400&gt; 4

	Met	Asp	Pro	Asp	Ser	Asp	Gln	Pro	Leu	Asn	Ser	Leu	Asp	Val	Lys	Pro
	1				5					10					15	
10	Leu	Arg	Lys	Pro	Arg	Ile	Pro	Met	Glu	Thr	Phe	Arg	Lys	Val	Gly	Ile
				20					25					30		
	Pro	Ile	Ile	Ile	Ala	Leu	Leu	Ser	Leu	Ala	Ser	Ile	Ile	Ile	Val	Val
				35				40					45			
	Val	Leu	Ile	Lys	Val	Ile	Leu	Asp	Lys	Tyr	Tyr	Phe	Leu	Cys	Gly	Gln
		50					55					60				
15	Pro	Leu	His	Phe	Ile	Pro	Arg	Lys	Gln	Leu	Cys	Asp	Gly	Glu	Leu	Asp
	65					70					75					80
	Cys	Pro	Leu	Gly	Glu	Asp	Glu	Glu	His	Cys	Val	Lys	Ser	Phe	Pro	Glu
				85						90					95	
20	Gly	Pro	Ala	Val	Ala	Val	Arg	Leu	Ser	Lys	Asp	Arg	Ser	Thr	Leu	Gln
				100						105					110	
	Val	Leu	Asp	Ser	Ala	Thr	Gly	Asn	Trp	Phe	Ser	Ala	Cys	Phe	Asp	Asn
			115					120						125		
	Phe	Thr	Glu	Ala	Leu	Ala	Glu	Thr	Ala	Cys	Arg	Gln	Met	Gly	Tyr	Ser
		130					135						140			
25	Ser	Lys	Pro	Thr	Phe	Arg	Ala	Val	Glu	Ile	Gly	Pro	Asp	Gln	Asp	Leu
	145					150					155					160
	Asp	Val	Val	Glu	Ile	Thr	Glu	Asn	Ser	Gln	Glu	Leu	Arg	Met	Arg	Asn
				165						170					175	
30	Ser	Ser	Gly	Pro	Cys	Leu	Ser	Gly	Ser	Leu	Val	Ser	Leu	His	Cys	Leu
			180						185					190		
	Ala	Cys	Gly	Lys	Ser	Leu	Lys	Thr	Pro	Arg	Val	Val	Gly	Gly	Glu	Glu
			195					200						205		
	Ala	Ser	Val	Asp	Ser	Trp	Phe	Trp	Gln	Val	Ser	Ile	Gln	Tyr	Asp	Lys
			210				215						220			
35	Gln	His	Val	Cys	Gly	Gly	Ser	Ile	Leu	Asp	Pro	His	Trp	Val	Leu	Thr
	225					230					235					240
	Ala	Ala	His	Cys	Phe	Arg	Lys	His	Thr	Asp	Val	Phe	Asn	Trp	Lys	Val
				245						250					255	
40	Arg	Ala	Gly	Ser	Asp	Lys	Leu	Gly	Ser	Phe	Pro	Ser	Leu	Ala	Val	Ala
			260						265					270		
	Lys	Ile	Ile	Ile	Ile	Glu	Phe	Asn	Pro	Met	Tyr	Pro	Lys	Asp	Asn	Asp
			275					280						285		
	Ile	Ala	Leu	Met	Lys	Leu	Gln	Phe	Pro	Leu	Thr	Phe	Ser	Gly	Thr	Val
		290					295						300			
45	Arg	Pro	Ile	Cys	Leu	Pro	Phe	Phe	Asp	Glu	Glu	Leu	Thr	Pro	Ala	Thr
	305					310						315				320
	Pro	Leu	Trp	Ile	Ile	Gly	Trp	Gly	Phe	Thr	Lys	Gln	Asn	Gly	Gly	Lys
				325						330					335	
50	Met	Ser	Asp	Ile	Leu	Leu	Gln	Ala	Ser	Val	Gln	Val	Ile	Asp	Ser	Thr
			340						345					350		
	Arg	Cys	Asn	Ala	Asp	Asp	Ala	Tyr	Gln	Gly	Glu	Val	Thr	Glu	Lys	Met
			355					360						365		
	Met	Cys	Ala	Gly	Ile	Pro	Glu	Gly	Gly	Val	Asp	Thr	Cys	Gln	Gly	Asp
		370				375						380				
55	Ser	Gly	Gly	Pro	Leu	Met	Tyr	Gln	Ser	Asp	Gln	Trp	His	Val	Val	Gly
	385					390					395					400
	Ile	Val	Ser	Trp	Gly	Tyr	Gly	Cys	Gly	Gly	Pro	Ser	Thr	Pro	Gly	Val
				405						410					415	
60	Tyr	Thr	Lys	Val	Ser	Ala	Tyr	Leu	Asn	Trp	Ile	Tyr	Asn	Val	Trp	Lys
				420					425					430		
	Asp	Arg	Thr	Ile	Gln	Arg	Ser	Cys	Asn	Ser	Pro	Gly	Thr	Gly	Leu	Val

```

      435              440              445
Ile Sln Gln Pro Ala Val Pro Leu Met Glu Leu Arg Ser Ala Arg His
      450              455              460
Thr His Arg Leu Thr Thr Cys Val Cys Phe Leu Ser Phe Pro Ala Leu
5  465              470              475              480
Gln Pro Leu Ser Pro Leu Cys Pro Phe Pro Trp Asp
      485              490

10  <210> 5
    <211> 609
    <212> DNA
    <213> Homo sapiens

15  <220>
    <221> CDS
    <222> (1...609)

20  <400> 5
atg gat cct gac agt gat caa cct ctc aac agc ctc gat gtc aaa ccc  65
Met Asp Pro Asp Ser Asp Gln Pro Leu Asn Ser Leu Asp Val Lys Pro
      10
25  ctg cgc aaa ccc cgt atc ccc atg gag acc ttc aga aag gtg ggg atc  96
Leu Arg Lys Pro Arg Ile Pro Met Glu Thr Phe Arg Lys Val Gly Ile
      20              25              30
30  ccc atc atc ata gca cca ctg agc ctg ggc agt atc atc att gtg gtc  144
Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val
      35              40              45
35  gtc ctc acc aag gtg att ctg gat aca tac tac ttc ctc tgc ggc cag  192
Val Leu Ile Lys Val Ile Ser Asp Lys Tyr Tyr Phe Leu Cys Gly Gln
      50              55              60
40  cct ctg ccc ctg ctg atc ccc agc aag cag ctg tgt gac gga gag ctg gac  240
Pro Leu His Phe Ile Pro Arg Lys Gln Leu Cys Asn Gly Glu Leu Asp
      65              70              75
45  tgt ccc ttc ggc gag gac gag cag tgc gtc aag agc ttc ccc gag  288
Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu
      85              90              95
50  ggg cct gca gtg gca gtc cgc ctg acc aag gac cga tcc aca ctg cag  336
Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Gln
      100              105              110
55  gtg ctg gac ttc gcc acc gga aac tgc ttc ttc gtc tgt ttc gac acc  384
Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn
      115              120              125
60  ttc aca gca gcc ctg gct cgg cca cac ttg gtg ctg cca gcc tcc cag  432
Phe Thr Ala Ala Leu Ala Arg Pro His Leu Val Leu Pro Ala Ser Gln
      130              135              140
      gga gag acc cag acc act gaa caa ggt ctg agc gct att gct aag cca  480
      Gly Glu Thr Gln Pro Thr Glu Gln Gly Leu Arg Gly Ile Ala Lys Pro
      145              150              155              160
60  aga agg aac ttc ccc aca cta ctg aat gga acc agc ctg tct tgt aaa  528

```

Arg Arg Asn Phe Pro Thr Leu Leu Asn Gly Ser Arg Leu Ser Cys Lys  
 165 170 175  
 5 agc cca gat cac tgc ggc atg gaa agc aga aag aaa ggg tcc gac cca 576  
 Ser Pro Asp His Cys Gly Leu Glu Arg Arg Arg Lys Gly Ser Ala Pro  
 180 185 190  
 10 ggc atg tcc gtc ttc acc cat ccc caa gaa tac 609  
 Ala Leu Ser Val Phe Thr His Pro Glu Ala Tyr  
 195 200  
 <210> 6  
 <211> 203  
 15 <212> PRT  
 <213> Homo sapiens  
 <400> 6  
 30 Met Asp Pro Asp Ser Asp Glu Pro Leu Asn Ser Leu Asp Val Lys Pro  
 5 10 15  
 Leu Arg Lys Pro Arg Ile Pro Met His Thr Phe Arg Lys Val Gly Ile  
 20 25 30  
 25 Pro Ile Ile Ile Ala Leu Leu Ser Leu Ala Ser Ile Ile Ile Val Val  
 35 40 45  
 Val Leu Ile Lys Val Ile Leu Asp Lys Tyr Tyr Phe Leu Cys Gly Glu  
 50 55 60  
 30 Pro Leu His Phe Ile Pro Arg Lys Glu Leu Cys Asp Gly Glu Leu Asp  
 65 70 75 80  
 35 Cys Pro Leu Gly Glu Asp Glu Glu His Cys Val Lys Ser Phe Pro Glu  
 85 90 95  
 Gly Pro Ala Val Ala Val Arg Leu Ser Lys Asp Arg Ser Thr Leu Glu  
 100 105 110  
 40 Val Leu Asp Ser Ala Thr Gly Asn Trp Phe Ser Ala Cys Phe Asp Asn  
 115 120 125  
 Phe Thr Ala Ala Leu Ala Arg Pro His Leu Val Leu Pro Ala Ser Glu  
 130 135 140  
 45 Gly Glu Thr Glu Pro Thr Glu Glu Gly Leu Arg Gly Ile Ala Lys Pro  
 145 150 155 160  
 50 Arg Arg Asn Phe Pro Thr Leu Leu Asn Gly Ser Arg Leu Ser Cys Lys  
 165 170 175  
 Ser Pro Asp His Cys Gly Leu Glu Arg Arg Arg Lys Gly Ser Ala Pro  
 180 185 190  
 55 Ala Leu Ser Val Phe Thr His Pro Glu Ala Tyr  
 195 200

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04141 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/57,  
9/64, 15/11, 15/10, C07K 19/00, 16/40, C12Q 1/37

D-64665 Alsbach (DE). MATZKU, Siegfried [DE/DE];  
Wetzbach 24, D-64673 Zwingenberg (DE). WILBERT,  
Oliver [DE/DE]; Liebfrauenstrasse 54, D-64289 Darm-  
stadt (DE).

(21) International Application Number: PCT/EP00/06211

(22) International Filing Date: 4 July 2000 (04.07.2000)

(74) Common Representative: MERCK PATENT GMBH;  
Frankfurter Str. 250, D-64293 Darmstadt (DE).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(30) Priority Data:  
99113428.9 12 July 1999 (12.07.1999) EP

Published:  
— With international search report.

(71) Applicant (*for all designated States except US*): MERCK  
PATENT GMBH [DE/DE]; Frankfurter Str. 250, D-64293  
Darmstadt (DE).

(88) Date of publication of the international search report:  
25 May 2001

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SÜNDERMANN,  
Britta [DE/DE]; Weinbergstrasse 6a, D-64285 Darmstadt  
(DE). HOFMANN, Uwe [DE/DE]; Hähnleinerstr. 42,

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SERIPANCRIN

(57) Abstract: Seripancrin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant tech-  
niques are disclosed. Also disclosed are methods for utilizing Seripancrin polypeptides and polynucleotides in diagnostic assays.

WO 01/04141 A3



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/06211

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7    C12N15/57    C12N9/64    C12N15/11    C12N15/10    C07K19/00 C07K16/40    C12Q1/37		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7    C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, PAJ, EMBL, WPI Data, BIOSIS		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PAOLONI-GIACOBINO A ET AL: "CLONING OF THE TMRSS2 GENE, WHICH ENCODES A NOVEL SERINE PROTEASE WITH TRANSMEMBRANE, LDLRA, AND SRCR DOMAINS AND MAPS TO 21Q22.3" GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 44, no. 3, 15 September 1997 (1997-09-15), pages 309-320, XP000856785 ISSN: 0888-7543 cited in the application the whole document	1-11
A	JP 09 149790 A (SUNTORY LTD) 10 June 1997 (1997-06-10) the whole document	1-11
-/--		
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-weight: bold;">15 February 2001</div>		Date of mailing of the international search report  <div style="text-align: center; font-weight: bold;">22/02/2001</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-weight: bold;">Gurdjian, D</div>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/06211

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 36550 A (INCYTE PHARMA INC ;CORLEY NEIL C (US); YUE HENRY (US); BANDMAN OLG) 22 July 1999 (1999-07-22) abstract; claims 1-23; figures SEQ.ID6,18	1-8,10, 11
P,X	WO 00 12758 A (RECIPON HERVE ;DIADEXUS LLC (US); SALCEDA SUSANA (US); SUN YONGMIN) 9 March 2000 (2000-03-09) abstract; claims 2-13; figure SEQ.ID.2	1-8,10, 11
P,X	WO 00 12708 A (BAKER KEVIN ;GENENTECH INC (US); GODDARD AUDREY (US); GURNEY AUSTI) 9 March 2000 (2000-03-09) abstract; claims 1-27; figures 155,,SEQ.ID.274,	1-8,10

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/06211

Patent document cited in search report	Publication date	Patent family m mber(s)	Publication date
JP 09149790 A	10-06-1997	NONE	
WO 9936550 A	22-07-1999	AU 2113599 A EP 1045913 A	02-08-1999 25-10-2000
WO 0012758 A	09-03-2000	NONE	
WO 0012708 A	09-03-2000	AU 5590899 A AU 6041399 A WO 0017353 A	21-03-2000 10-04-2000 30-03-2000